H. Lundbeck A/S (0ND5.IL)

32.92 -0.12 (-0.36%) At close: 06:45PM BST

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 5,600

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Joerg Hornstein	CFO & Exec. VP of Corp. Functions	3.4M	N/A	1977
Mr. Jacob Tolstrup	Exec. VP of Commercial Operations	8.2M	N/A	1972
Mr. Lars Bang	Exec. VP of Product Devel. & Supply	7.7M	N/A	1962
Dr. Per Johan Luthman	Exec. VP of R&D	8.6M	N/A	1959
Mr. Charl van Zyl	Pres & CEO	N/A	N/A	1967
Dr. Tarek Samad Ph.D.	Sr. VP & Head of Research	N/A	N/A	N/A
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/A	N/A	N/A
Ms. Elise Hauge	Exec. VP of People & Communication	N/A	N/A	1967
Mr. Ole Chrintz	Sr. VP of International Markets	N/A	N/A	1958
Mr. Keld Flintholm Jorgensen	Exec. VP of Corp. Strategy & Bus. Devel.	N/A	N/A	1971

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Corporate governance

H. Lundbeck A/S’s ISS governance QualityScore as of 1 October 2023 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.